Issue 9/2012

  • Is gene therapy finally coming into its own?

    In this issue:


    Is gene therapy finally coming into its own?

    After a balancing act that went down to the wire with regulators – and left its predecessor company bankrupt – uniQure biotherapies now looks set to become the first pharma company to gain approval for a gene therapy in Europe. the concept of ‘curing’ rare inherited diseases by altering a patient’s genome in key cells has been around for decades. But disastrous, highly-publicised failures to harness the technology in the past frightened off developers and patients alike. Now that looks set to change.

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/9/pos/1.html?sort=asc&cHash=2aa63e7a3c47f54d547eeaaa494e591b

Kurszettel

Alle Kurse

TOP

  • ADDEX3.13 CHF4.68%
  • CO.DON3.15 EUR4.30%
  • BB BIOTECH146.25 EUR2.17%

FLOP

  • WILEX2.35 EUR-5.24%
  • SANTHERA89.15 CHF-3.10%
  • EVOTEC2.93 EUR-2.33%

TOP

  • SANTHERA89.15 CHF31.2%
  • CO.DON3.15 EUR26.0%
  • PAION3.01 EUR24.4%

FLOP

  • ADDEX3.13 CHF-22.3%
  • EVOTEC2.93 EUR-21.2%
  • MEDIGENE3.95 EUR-15.1%

TOP

  • SANTHERA89.15 CHF2117.7%
  • CO.DON3.15 EUR250.0%
  • PAION3.01 EUR189.4%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.67 EUR-40.6%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 17.09.2014